Hims Hers Health Inc
For the period ended Mar 31, 2024. Filed May 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 6, 2024
HIMS$19.13-16.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows (Unaudited)
(In Thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Operating activities | ||
| Net income (loss) | $11,128 | $(10,067) |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||
| Depreciation and amortization | 3,001 | 2,117 |
| Stock-based compensation | 19,032 | 14,167 |
| Change in fair value of liabilities | — | 295 |
| Net accretion on securities | (1,077) | (1,041) |
| Impairment of long-lived assets | 75 | 429 |
| Non-cash operating lease cost | 574 | 448 |
| Non-cash acquisition-related costs | — | 566 |
| Non-cash other | 408 | 124 |
| Changes in operating assets and liabilities: | ||
| Inventory | (7,362) | 865 |
| Prepaid expenses and other current assets | (6,708) | (4,984) |
| Other long-term assets | (47) | 5 |
| Accounts payable | 3,602 | 3,955 |
| Accrued liabilities | (2,258) | 1,673 |
| Deferred revenue | 6,002 | 1,394 |
| Operating lease liabilities | (532) | (463) |
| Net cash provided by operating activities | 25,838 | 9,483 |
| Investing activities | ||
| Purchases of investments | (70,700) | (40,687) |
| Maturities of investments | 97,700 | 39,084 |
| Investment in website development and internal-use software | (3,377) | (1,875) |
| Purchases of property, equipment, and intangible assets | (10,581) | (635) |
| Net cash provided by (used in) investing activities | 13,042 | (4,113) |
| Financing activities | ||
| Proceeds from exercise of vested stock options | 5,070 | 245 |
| Payments for taxes related to net share settlement of equity awards | (7,314) | (3,657) |
| Repurchases of common stock | (28,064) | — |
| Net cash used in financing activities | (30,308) | (3,412) |
| Foreign currency effect on cash and cash equivalents | 2 | 15 |
| Increase in cash, cash equivalents, and restricted cash | 8,574 | 1,973 |
| Cash, cash equivalents, and restricted cash at beginning of period | 97,519 | 47,628 |
| Cash, cash equivalents, and restricted cash at end of period | $106,093 | $49,601 |
| Reconciliation of cash, cash equivalents, and restricted cash | ||
| Cash and cash equivalents | $105,237 | $48,745 |
| Restricted cash | 856 | 856 |
| Total cash, cash equivalents, and restricted cash | $106,093 | $49,601 |
| Supplemental disclosures of cash flow information | ||
| Cash paid for taxes | $126 | $286 |
| Non-cash investing and financing activities | ||
| Purchases of property and equipment included in accounts payable and accrued liabilities | $594 | $1,290 |
| Right-of-use asset obtained in exchange for lease liability | 2,174 | — |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.